Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer

Sharmila Upadhya, Subramanya Upadhya, D. M. Vasudevan

Research output: Contribution to journalArticle

Abstract

The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalIndian Journal of Clinical Biochemistry
Volume18
Issue number1
DOIs
Publication statusPublished - 01-01-2003
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Colorectal Neoplasms
Therapeutics
Oncology
tissue polypeptide specific antigen
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{86bf14dccd5e4a968de58d7b5bba9ab6,
title = "Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer",
abstract = "The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4{\%} in group I and 95.5{\%} in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70{\%} and 30{\%} in group I and 100{\%} in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.",
author = "Sharmila Upadhya and Subramanya Upadhya and Vasudevan, {D. M.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1007/BF02867664",
language = "English",
volume = "18",
pages = "46--51",
journal = "Indian Journal of Clinical Biochemistry",
issn = "0970-1915",
publisher = "Springer India",
number = "1",

}

Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer. / Upadhya, Sharmila; Upadhya, Subramanya; Vasudevan, D. M.

In: Indian Journal of Clinical Biochemistry, Vol. 18, No. 1, 01.01.2003, p. 46-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer

AU - Upadhya, Sharmila

AU - Upadhya, Subramanya

AU - Vasudevan, D. M.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.

AB - The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0042477651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042477651&partnerID=8YFLogxK

U2 - 10.1007/BF02867664

DO - 10.1007/BF02867664

M3 - Article

VL - 18

SP - 46

EP - 51

JO - Indian Journal of Clinical Biochemistry

JF - Indian Journal of Clinical Biochemistry

SN - 0970-1915

IS - 1

ER -